VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression

Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on the discordance between clinically and genomically-defined smoldering myeloma, explaining how this can be used to find patients at high risk of progression to multiple myeloma and initiate treatment early. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter